parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.41 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in tuft cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 242	0.85
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 0497

receipt 0503: EPM2A in dopamine neurons, braak

power: full sample +0.13 (p 0.609, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.14 (p 0.579, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.15 (p 0.555, n 18). could be the mix.
skeptic: leave-one-out range +0.03 to +0.29, sign flips 0; without severely affected donors +0.13 (p 0.609, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EPM2A in dopamine neurons.

case closed: nothing better to follow up.

receipt 0502: EPM2A in astrocytes, braak

power: full sample -0.13 (p 0.609, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.13 (p 0.609, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.09 (p 0.728, n 18). could be the mix.
skeptic: leave-one-out range -0.25 to +0.01, sign flips 1; without severely affected donors -0.13 (p 0.609, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EPM2A in astrocytes.

case closed: nothing better to follow up.

loading the receipts